James Scibetta
Direttore/Membro del Consiglio presso MATINAS BIOPHARMA HOLDINGS, INC.
Patrimonio netto: 106 593 $ in data 31/05/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Gary Crocker | M | 72 | 20 anni | |
| Jerome Jabbour | M | 50 | 11 anni | |
| Kristen Williams | F | 50 |
Bioenvision, Inc.
 Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 17 anni |
| Herbert Conrad | M | 91 | 11 anni | |
| Eric Ende | M | 55 | 7 anni | |
| Kathryn Corzo | F | 63 |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 4 anni |
| Lori Braender | F | 68 | 6 anni | |
| Paul Hastings | M | 64 | 13 anni | |
| Robert DuBridge | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 8 anni |
| Marco Taglietti | M | 64 | 3 anni | |
| Mark Froimson | M | 63 | 7 anni | |
| Julie Krop | M | 57 | 3 anni | |
| Theresa Matkovits | M | 56 | 6 anni | |
| Mark Kronenfeld | M | 69 | 11 anni | |
| Natasha Giordano | F | 62 | 4 anni | |
| Laura Brege | F | 66 | 13 anni | |
| Lauren Riker | F | 45 | 12 anni | |
| Matthew Wikler | M | 74 | 6 anni | |
| Detlev Biniszkiewicz | M | 56 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Hui Liu | M | 56 | 4 anni | |
| Susan Mesco | F | - | 9 anni | |
| Michael Martin | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Keith Kucinski | M | 55 | 5 anni | |
| Ittai Harel | M | 56 |
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| Jessica Atkinson | F | - |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | 2 anni |
| Charles Reinhart | M | 63 | 13 anni | |
| Sangeeta Bhatia | M | 55 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| James Ferguson | M | 70 | 5 anni | |
| Steven Kafka | M | 54 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| Thomas Hoover | M | 55 | 3 anni | |
| Christoph Westphal | M | 56 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| William Greene | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 5 anni |
| Peter Hutt | M | 89 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| A. Toth | M | 65 | 4 anni | |
| Daniel Janney | M | 58 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| Dan Hicklin | M | 61 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Pam Stetkiewicz | M | - |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Mark A. D'Souza | M | - |
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| John C. Houghton | M | 60 | 3 anni | |
| Gerald J. Kochanski | M | 69 | 5 anni | |
| Keith Kendall | M | 66 | 16 anni | |
| Daron Evans | M | 50 | 7 anni | |
| Norman J. Barta | M | 65 | 10 anni | |
| Roelof Rongen | M | 59 | 5 anni | |
| Robert J. Mulroy | M | 59 | 17 anni | |
| Christopher Barry Wood | M | 78 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 8 anni |
| David Luci | M | 57 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 5 anni |
| Douglas Bratton | M | 65 | 17 anni | |
| Gordon J. Fehr | M | 90 |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | 17 anni |
| Pat LePore | M | 69 | 3 anni | |
| Stefano Ferrari | M | 55 | 5 anni | |
| James van B. Dresser | M | 82 | 15 anni | |
| Gary Gaglione | M | 72 | 5 anni | |
| Mark Walters | M | 69 | 5 anni | |
| Brian L. Hamilton | M | 76 | 2 anni | |
| Me Lisane Dostie | F | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | 8 anni |
| Sylvie Bouchard | M | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| Sarah Nash | F | 70 | 8 anni | |
| Nancy Lurker | F | 66 | 4 anni | |
| Richard Scranton | M | 57 | 9 anni | |
| Yvonne Greenstreet | M | 61 | 9 anni | |
| Dominick DiPaolo | M | 49 | 1 anni | |
| Hans-Peter Gerber | M | 61 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 2 anni |
| Scott Braunstein | M | 60 | 3 anni | |
| Carl Gordon | M | 59 | 5 anni | |
| Sylvain Guénette | M | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| Dennis L. Winger | M | 77 | 5 anni | |
| Roy Winston | M | 63 | - | |
| Walter M. Lovenberg | M | 89 | 12 anni | |
| Gary H. Slatko | M | 67 | - | |
| Luke Evnin | M | 60 | 7 anni | |
| Yoshimaru Yamamoto | M | - |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | - |
| Paul R. Ellwood | M | - | - | |
| François Ravenelle | M | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | 6 anni |
| Julia Brown | F | 76 |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| Vinay Shah | M | 62 | 8 anni | |
| Douglas Kling | M | 50 | 2 anni | |
| Richard Kahr | M | - | 8 anni | |
| Robert J. Weiland | M | 64 | - | |
| Kathleen Gallagher | F | - | 13 anni | |
| Dennis Mcloughlin | M | 58 | - | |
| David H. Donabedian | M | - |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| Fazal R. Khan | M | 74 | - | |
| Charles Laranjeira | M | 58 | 6 anni | |
| Gary Patou | M | 65 | 6 anni | |
| Raphael J. Mannino | M | 77 | 7 anni | |
| Peter C. Lewis | M | - | - | |
| Fred Middleton | M | 74 | 7 anni | |
| Joseph Cooper | M | 66 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 1 anni |
| Vincent Simmon | M | - | - | |
| Thomas Scott Nelson | M | - |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | - |
| Andrew Saunders | M | - |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 2 anni |
| James B. Jones | M | 59 | - | |
| Edward J. Stewart | M | 53 | 16 anni | |
| Steven Elms | M | 60 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 5 anni |
| Tim M. Ciaccio | M | - | - | |
| Lori Kunkel | M | 66 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 6 anni |
| Taunia S. Markvicka | M | 56 | 8 anni | |
| William J. Lambert | M | 65 | 4 anni | |
| Jim Murray | M | - | 14 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 94 | 94.00% |
| Canada | 7 | 7.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- James Scibetta
- Contatti personali
